BrightWater Medical receives FDA clearance for convertible stent

The Food and Drug Administration recently gave market clearance to BrightWater Medical’s ConvertX Nephroureteral Stent System.

Advertisement

The stent is intended to treat ureteral obstructions that prevent urine in the kidneys from draining into the bladder.

The device can convert from a catheter to a stent — first draining urine from the patient before acting as a stent to fix the blockage — eliminating clinician’s need to perform two separate procedures.

“The ConvertX System saves the patient the risk and discomfort of an additional second interventional procedure and may reduce healthcare costs, free up the hospital’s angio suite for other procedures and save the IR procedural time that can be devoted to care of other patients,” said Bob Smouse, MD, founder and CEO of Mountain View, Calif.-based BrightWater Medical.

More articles on supply chain:

Court orders contracted pilots for Amazon, DHL to return to work after strike
DEA bans furanyl fentanyl
4 threats to the US blood supply

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.